Signaling and Feedback Networks Underlying Senstivity and Resistance to Kinase Inhibitors in Oncogene Addicted Cancers
Targeted therapies have begun to be developed and approved in the clinic over the past several decades to treat cancers with specific genetic alterations. In non-small cell lung cancer (NSCLC), patients harboring EGFR activating mutations often respond to the EGFR inhibitors gefitinib/erlotinib, exh...
| Main Author: | |
|---|---|
| Other Authors: | |
| Language: | en_US |
| Published: |
Harvard University
2013
|
| Subjects: | |
| Online Access: | http://dissertations.umi.com/gsas.harvard:10007 http://nrs.harvard.edu/urn-3:HUL.InstRepos:10121967 |